AXSOME THERAPEUTICS, INC. (AXSM) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$49.65M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$63.36M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$46.11M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$36.71M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$49.65M | (m) | $218.38M | (m) | $450.00K* | -$32.95M* | (m) | $46.23M | $208.14M | $128.00K |
| 2026-03-31 | Reported | (m) | -$63.36M | (m) | $191.20M | (m) | $121.00K | -$20.70M | (m) | $52.68M | $185.00M | $0.00 |
| 2025-09-30 | Reported | (m) | -$46.11M | (m) | $170.99M | (m) | $58.00K* | $1.05M* | (m) | $40.16M | $150.24M | $0.00 |
| 2025-06-30 | Reported | (m) | -$36.71M | (m) | $150.04M | (m) | $13.00K* | -$32.42M* | (m) | $49.54M | $130.28M | -$960.00K |
| 2025-03-31 | Reported | (m) | -$56.98M | (m) | $121.46M | (m) | $338.00K | -$43.38M | (m) | $44.78M | $120.79M | $0.00 |
| 2024-09-30 | Reported | (m) | -$62.62M | (m) | $104.76M | (m) | $90.00K* | -$18.63M* | (m) | $45.39M | $95.56M | $0.00 |
| 2024-06-30 | Reported | (m) | -$78.05M | (m) | $87.17M | (m) | $52.00K* | -$30.11M* | (m) | $49.85M | $103.55M | $0.00 |
| 2024-03-31 | Reported | (m) | -$67.28M | (m) | $75.00M | (m) | $98.00K | -$53.47M | (m) | $36.83M | $98.97M | $0.00 |
| 2023-09-30 | Reported | (m) | -$62.12M | (m) | $57.79M | (m) | $371.00K* | -$53.55M* | (m) | $28.77M | $83.19M | -$678.00K |
| 2023-06-30 | Reported | (m) | -$65.06M | (m) | $46.70M | (m) | $133.00K* | -$55.35M* | (m) | $20.58M | $78.94M | -$617.00K |
| 2023-03-31 | Reported | (m) | -$6.37M | (m) | $94.58M | (m) | $71.00K | -$5.82M | (m) | $17.79M | $74.19M | $2.58M |
| 2022-09-30 | Reported | (m) | -$42.41M | (m) | $16.85M | (m) | $66.00K* | -$22.76M* | (m) | $14.88M | $40.89M | $0.00* |
| 2022-06-30 | Reported | (m) | -$39.18M | (m) | $8.82M | (m) | $241.00K* | -$33.54M* | (m) | $15.79M | $31.16M | $0.00* |
| 2022-03-31 | Reported | (m) | -$38.29M | (m) | (m) | (m) | $214.00K | -$32.65M | (m) | $12.59M | $25.70M | $0.00 |
| 2021-09-30 | Reported | (m) | -$33.41M | (m) | (m) | (m) | $258.68K* | -$26.78M* | (m) | $13.18M | $20.23M | $0.00* |
| 2021-06-30 | Reported | (m) | -$30.85M | (m) | (m) | (m) | $18.88K* | -$25.39M* | (m) | $14.50M | $16.34M | $0.00* |
| 2021-03-31 | Reported | (m) | -$27.84M | (m) | (m) | (m) | $30.00K | -$27.22M | (m) | $16.60M | (m) | $0.00 |
| 2020-09-30 | Reported | (m) | -$21.13M | (m) | (m) | (m) | $14.85K* | -$15.73M* | (m) | $14.80M | (m) | $0.00* |
| 2020-06-30 | Reported | (m) | -$17.78M | (m) | (m) | (m) | $1.43K* | -$18.90M* | (m) | $10.54M | (m) | $0.00* |
| 2020-03-31 | Reported | (m) | -$32.49M | (m) | (m) | (m) | $9.33K | -$23.27M | (m) | $27.52M | (m) | $0.00 |
| 2019-09-30 | Reported | (m) | -$18.95M | (m) | (m) | (m) | $3.20K* | -$10.63M* | (m) | $15.84M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$13.45M | (m) | (m) | (m) | (m) | -$8.68M* | (m) | $11.00M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$10.42M | (m) | (m) | (m) | (m) | -$9.50M | (m) | $7.60M | (m) | (m) |
| 2018-12-31 | Reported | (m) | $9.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$8.24M | (m) | (m) | (m) | $8.48K* | -$5.91M* | (m) | $6.04M | (m) | -$217.42K |
| 2018-06-30 | Reported | (m) | -$7.99M | (m) | (m) | (m) | $9.64K* | -$7.67M* | (m) | $5.55M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$7.16M | (m) | (m) | (m) | $14.58K | -$6.68M | (m) | $4.75M | (m) | (m) |
| 2017-12-31 | Reported | (m) | $6.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | Reported | (m) | $6.30M | (m) | (m) | (m) | $3.60K* | -$6.45M* | (m) | $4.47M | (m) | -$207.11K |
| 2017-06-30 | Reported | (m) | $6.75M | (m) | (m) | (m) | $3.40K* | -$7.10M* | (m) | $5.01M | (m) | (m) |
| 2017-03-31 | Reported | (m) | $7.67M | (m) | (m) | (m) | $2.90K | -$6.64M | (m) | $5.99M | (m) | (m) |
| 2016-12-31 | Reported | (m) | $7.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | Reported | (m) | $7.21M | (m) | (m) | (m) | $76.25K* | -$4.80M* | (m) | $5.57M | (m) | (m) |
| 2016-06-30 | Reported | (m) | $6.83M | (m) | (m) | (m) | $11.60K* | -$5.31M* | (m) | $5.30M | (m) | (m) |
| 2016-03-31 | Reported | (m) | $5.88M | (m) | (m) | (m) | $10.65K | -$3.95M | (m) | $4.53M | (m) | (m) |
| 2015-12-31 | Reported | (m) | $3.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | Reported | (m) | $2.02M | (m) | (m) | (m) | $4.41K* | -$1.92M* | (m) | $1.52M | (m) | (m) |
| 2015-06-30 | Reported | (m) | $2.08M | (m) | (m) | (m) | $1.42K* | -$2.11M* | (m) | $1.63M | (m) | (m) |
| 2015-03-31 | Reported | (m) | $1.93M | (m) | (m) | (m) | $10.26K | -$1.16M | (m) | $1.42M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$166.76M | (m) | $638.50M | (m) | $480.00K | -$93.41M | (m) | $183.28M | $570.60M | -$530.00K |
| 2024-12-31 | Reported | (m) | -$280.56M | (m) | $385.69M | (m) | $270.00K | -$128.41M | (m) | $187.08M | $411.36M | $85.00K |
| 2023-12-31 | Reported | (m) | -$231.82M | (m) | $270.60M | (m) | $582.00K | -$145.08M | (m) | $97.94M | $323.12M | $960.00K |
| 2022-12-31 | Reported | (m) | -$179.80M | (m) | $50.04M | (m) | $702.00K | -$116.51M | (m) | $57.95M | $159.25M | $0.00 |
| 2021-12-31 | Reported | (m) | -$124.71M | (m) | (m) | (m) | $308.00K | -$108.23M | (m) | $58.06M | $66.65M | $0.00 |
| 2020-12-31 | Reported | (m) | -$99.14M | (m) | (m) | (m) | $45.89K | -$78.46M | (m) | $70.24M | $28.90M | $0.00 |
| 2019-12-31 | Reported | (m) | -$67.25M | (m) | (m) | (m) | $16.12K | -$46.38M | (m) | $53.65M | (m) | $0.00 |
| 2019-09-30 | Rolling | (m) | -$33.37M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | Rolling | (m) | -$22.66M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | Rolling | (m) | -$17.20M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$32.85M | (m) | (m) | (m) | $32.70K | -$30.05M | (m) | $23.50M | (m) | $0.00 |
| 2018-12-31 | Rolling | (m) | -$13.95M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Rolling | (m) | -$16.95M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | Rolling | (m) | -$2.41M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | Rolling | (m) | $12.33M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$27.16M | (m) | (m) | (m) | $9.90K | -$26.47M | (m) | $19.96M | (m) | $0.00 |
| 2017-12-31 | Rolling | (m) | $27.16M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | Rolling | (m) | $28.35M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | Rolling | (m) | $29.26M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | Rolling | (m) | $29.33M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$27.54M | (m) | (m) | (m) | $104.56K | -$21.28M | (m) | $21.20M | (m) | $0.00 |
| 2016-12-31 | Rolling | (m) | $27.54M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | Rolling | (m) | $23.07M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | Rolling | (m) | $17.89M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | Rolling | (m) | $13.15M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$9.20M | (m) | (m) | (m) | $20.20K | -$7.44M | (m) | $6.78M | (m) | (m) |
| 2015-12-31 | Rolling | (m) | $9.20M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$5.67M | (m) | (m) | (m) | (m) | -$4.60M | (m) | $4.28M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |